EpimAb + Innovent Enter $120 Million Bispecific Antibody Partnership

Shanghai ­­– June 9, 2016 – Cooley advised Shanghai-based EpimAb Biotherapeutics on its first licensing deal for its bispecific antibody platform technology to Innovent Biologics.

EpimAb is a biopharmaceutical company specializing in bispecific antibodies. Innovent Biologics is a Suzhou-based leading biopharmaceutical company focused on the discovery, development and manufacturing of complex, high-end biologics for both the Asian and global markets.

Under the terms of the agreement, Innovent will buy the rights to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return for commercialization rights to these molecules in China, EpimAb is eligible to receive an upfront payment and total milestones of up to $120 million, plus royalties.

The Shanghai-based corporate team advising EpimAb included James Lu and Bin Wang. Nan Wu and Meghann Teague served as the company’s patent counsel.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Related Contacts
James Lu Partner, Shanghai
Bin Wang Associate, Beijing